SELECT: The selenium and vitamin E cancer prevention trial

Eric A. Klein, Ian M. Thompson, Scott M. Lippman, Phyllis J. Goodman, Demetrius Albanes, Philip R. Taylor, Charles Coltman

Research output: Contribution to journalArticlepeer-review

120 Scopus citations


Purpose: Growing evidence suggests that both selenium and vitamin E may reduce the risk of prostate cancer. SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiologic evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of both agents were included in the analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the schema of SELECT. Results: Preclinical, epidemiologic, and Phase III data suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial and the rapid accrual of SELECT during its first year demonstrate the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Issue number1
StatePublished - Jan 2003


  • Chemoprevention
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'SELECT: The selenium and vitamin E cancer prevention trial'. Together they form a unique fingerprint.

Cite this